T-Cells and Cancer: Recent Advances and Updates

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 July 2024 | Viewed by 83

Special Issue Editor

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Interests: aryl hydrocarbon receptor (AhR) signaling; innate immune response; metabolic checkpoint; tumor cell-intrinsic resistance mechanism

Special Issue Information

Dear Colleagues,

T cells are circulating soldiers in our adaptive immune system, responding to exogenous and endogenous threats. In recognition of these signals, T cells differentiate into different subsets, which act in concert to ensure immune homeostasis and protect us from pathologies, such as cancer. Simply put, these subsets can be grouped into functional effector T cells (Teff) and suppressive regulatory T cells (Treg).

Unfortunately, the microenvironment in cancer renders T cells dysfunctional by suppressing Teff and promoting Treg. To overcome this barrier and elevate protective T cell-mediated anti-tumor immunity, ground-breaking immunotherapeutic strategies (IOs) have been pursued in recent years, including blocking immune checkpoints (ICBs) and generating super-T cells (e.g, CAR-T cells). Although IOs have induced great therapeutic benefits in some patients, challenges remain. To name a few, therapeutic resistance is common, mechanistic understanding is limited, and strategies of overcoming resistance are largely unknown.

In this Special Issue, we welcome cutting-edge research papers, constructive reviews, and insightful perspectives on T cells, the warriors that could eventually combat cancer.

Dr. Lewis Shi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • T cells
  • CAR-T cells
  • adaptive immune system
  • immune homeostasis
  • cancer microenvironment
  • immune checkpoints
  • T cell-mediated anti-tumor immunity
  • therapeutic resistance

Published Papers

This special issue is now open for submission.
Back to TopTop